Blood pressure and heart rate in aripiprazole once – monthly and paliperidone 1 and 3-month long-acting preparations
Blood pressure and heart rate in aripiprazole once – monthly and paliperidone 1 and 3-month long-acting preparations
Objective: This study aims to evaluate the blood pressure and heart rates of the patients treated with aripiprazole once-monthly, paliperidone 1-month, and paliperidone 3-month long-acting injections. Patients and Methods: This study was a non-invasive observational study. Subjects using the same long-acting injection preparation for at least four months without skipped injections were assigned to 3 groups according to their treatments. They were screened starting from routine injection day and monthly for four months. Heart rate, systolic blood pressure, and diastolic blood pressure were recorded for each subject. Results: Systolic and diastolic blood pressure among the three treatment groups demonstrated no statistical significance. The heart rate of the paliperidone 3-month group was significantly higher than the aripiprazole once-monthly group. However, the mean heart rate was within the physiological limits. Thus, a clinical significance can hardly be attributed. Conclusion: Aripiprazole once-monthly, paliperidone 1-month, and paliperidone 3-month long-acting injections are non-inferior regarding heart rate, systolic and diastolic blood pressure during the maintenance treatment.
___
- [1] Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R.
An evaluation of variation in published estimates of
schizophrenia prevalence from 1990-2013: A systematic
literature review. BMC Psychiatry 2015; 15:193. doi: 10.1186/
s12888.015.0578-7
- [2] Taylor DM, Barnes TR, Young AH. The Maudsley Prescribing
Guidelines in Psychiatry. 13th ed. Hoboken, NJ: Wiley-
Blackwell. 2020.
- [3] Valsecchi P, Barlati S, Garozzo A, et al. Paliperidone palmitate
in short – and long-term treatment of schizophrenia. Riv
Psichiatr 2019; 54:235-48. doi: 10.1708/3281.32542
- [4] Potkin SG, Preda A. Aripiprazole once-monthly longacting
injectable for the treatment of schizophrenia. Expert
Opin Pharmacother 2016; 17:395-407. doi:
10.1517/14656.566.2015.1114100
- [5] Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular
depot as maintenance treatment in patients with schizophrenia:
A 52-week, multicenter, randomized, double-blind, placebocontrolled
study. J Clin Psychiatry 2012; 73:617-24. doi:
10.4088/JCP.11m07530
- [6] Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole
once-monthly for treatment of schizophrenia: double-blind,
randomised, non-inferiority study. Br J Psychiatry 2014;
205:135-44. doi: 10.1192/bjp.bp.113.134213
- [7] Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel
antipsychotic, is a high-affinity partial agonist at human
dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302:381-
9. doi: 10.1124/jpet.102.033175
- [8] Bishara D. Once-monthly paliperidone injection for the
treatment of schizophrenia. Neuropsychiatr Dis Treat 2010;
6:561-72. doi: 10.2147/NDT.S8505
- [9] Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of
antipsychotic drugs in patients with chronic schizophrenia. N
Engl J Med 2005; 353:1209-23. doi: 10.1056/NEJMoa051688
- [10] Edinoff AN, Doppalapudi PK, Orellana C, et al. Paliperidone
3-month ınjection for treatment of schizophrenia: a narrative
review. Front Psychiatry 2021; 12:699748. doi: 10.3389/
fpsyt.2021.699748
- [11] Ravenstijn P, Remmerie B, Savitz A, et al. Pharmacokinetics,
safety, and tolerability of paliperidone palmitate 3-month
formulation in patients with schizophrenia: A phase-1, singledose,
randomized, open-label study. J Clin Pharmacol 2016;
56:330-9. doi:10.1002/jcph.597
- [12] Naber D, Hansen K, Forray C, et al. Qualify: a randomized headto-
head study of aripiprazole once-monthly and paliperidone
palmitate in the treatment of schizophrenia. Schizophr Res
2015; 168:498-504. doi: 10.1016/j.schres.2015.07.007
- [13] Haddad PM, Tiihonen J, Haukka J, Taylor M, Patel MX,
Korhonen P. The place of observational studies in assessing
the effectiveness of depot antipsychotics. Schizophr Res 2011;
131:260–1. doi: 10.1016/j.schres.2011.05.022
- [14] Levine M, Ruha AM. Overdose of atypical antipsychotics:
clinical presentation, mechanisms of toxicity and
management. CNS Drugs 2012; 26:601-11. doi:
10.2165/11631.640.000000000-00000
- [15] Fisher J, Taori G, Braitberg G, Graudins A. Methylene blue
used in the treatment of refractory shock resulting from
drug poisoning. Clin Toxicol (Phila) 2014; 52:63-65. doi:
10.3109/15563.650.2013.870343
- [16] Buckley NA, Sanders P. Cardiovascular adverse effects
of antipsychotic drugs. Drug Saf 2000; 23:215-28. doi:
10.2165/00002.018.200023030-00004
- [17] Shah S, Joshi D. Tolerability and efficacy of paliperidone ER
compared to olanzapine in the treatment of schizophrenia: A
randomized, double-blind, multicentric trial. Ind Psychiatry J
2011; 20:25-31. doi: 10.4103/0972-6748.98411
- [18] Parks KA, Parks CG, Yost JP, Bennett JI, Onwuameze OE.
Acute blood pressure changes associated with antipsychotic
administration to psychiatric ınpatients. Prim Care
Companion CNS Disord 2018; 20:18m02299. doi: 10.4088/
PCC.18m02299
- [19] Garcia-Portilla MP, Llorca PM, Maina G, et al. Symptomatic
and functional outcomes after treatment with paliperidone
palmitate 3-month formulation for 52 weeks in
patients with clinically stable schizophrenia. Ther Adv
Psychopharmacol 2020; 25;10:204.512.5320926347. doi:
10.1177/204.512.5320926347
- [20] Uzun AD, Sapmaz ŞY, Öztürk M, Kandemir H. hypertension
ınduced by aripiprazole use in an autistic child patient. Clin
Psychopharmacol Neurosci 2019; 17:556-8. doi: 10.9758/
cpn.2019.17.4.556
- [21] Kato T, Mizoguchi Y, Monji A, et al. Inhibitory effects of
aripiprazole on interferon-γ-induced microglial activation
via intracellular Ca2+ regulation in vitro. J Neurochem 2008;
106:815-825. doi: 10.1111/j.1471-4159.2008.05435.x
- [22] Borras L, Constant EL, Eytan A, Huguelet P. Hypertension and
aripiprazole. Am J Psychiatry 2005; 162:2392. doi: 10.1176/
appi.ajp.162.12.2392
- [23] Yasui-Furukori N, Fujii A. Worsened hypertension control
induced by aripiprazole. Neuropsychiatr Dis Treat 2013;
9:505-7. doi: 10.2147/NDT.S43950.
- [24] Paton C, Duffett R, Harrington M, Lelliott P, Okocha C, Sensky
T. Patterns of antipsychotic and anticholinergic prescribing for
hospital inpatients. J. Psychopharmacol 2003; 17:223-9. doi:
10.1177/026.988.1103017002012
- [25] Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC.
Cardiovascular side-effects of antipsychotic drugs: The role
of the autonomic nervous system. Pharmacol Ther 2012;
135:113-22. doi: 10.1016/j.pharmthera.2012.04.003
- [26] Orlins Z, Barnett B. Tachycardia during treatment with
risperidone and paliperidone palmitate in a patient without
previous cardiovascular disease. Case Rep Psychiatr 2021;
2021:9954991. doi: 10.1155/2021/9954991
- [27] Tagne Nouemssi AB. Risperidone-associated sinus tachycardia
potentiated bypaliperidone palmitate in a patient with no prior cardiovascular
disease: role of risperidone-related autonomic instability. BML
Case Rep 2018;2018: bcr201.722.1771. doi: 10.1136/bcr-2017-
221771
- [28] Grubisha MJ, Brennan JL, Douaihy A. Isolated sinus
tachycardia following reinitiation of risperidone in a patient
with suspected autonomic hypersensitivity, Journal of
pharmacology & pharmacotherapeutics, 2015;6: 42-44. doi:
10.4103/0976-500X.149147
- [29] Oner T, Akdeniz C, Adaletli H. Multifocal atrial tachycardia
caused by risperidone. Int J Cardiol 2016; 203:855-7. doi:
10.1016/j.ijcard.2015.10.234
- [30] Borek HA and Charlton NP. Accidental pediatric paliperidone
ingestion resulting in delayed profound tachycardia. J Emerg
Med 2019; 57:109-11. doi: 10.1016/j.jemermed.2019.06.049
- [31] Davidson M, Emsley R, Kramer M, et al. Efficacy, safety
and early response of paliperidone extended-release tablets
(paliperidone ER): results of a 6-week, randomized, placebocontrolled
study. Schizophrenia Research 2007; 93:117-30.
doi: 10.1016/j.schres.2007.03.003
- [32] Polcwiartek C, Sneider B, Graff C, et al. The cardiac
safety of aripiprazole treatment in patients at high risk for
torsade: a systematic review with a meta-analytic approach.
Psychopharmacology (Berl) 2015; 232:3297-308. doi: 10.1007/
s00213.015.4024-9
- [33] Torgovnick J, Sethi NK, Arsura E. Aripiprazole-induced
orthostatic hypotension and cardiac arrhythmia. Psychiatry
Clin Neurosci 2008; 62:485. doi: 10.1111/j.1440-
1819.2008.01833.x
- [34] Shao Q, Quan W, Jia X, Chen J, Ma S, Zhang X. Severe
arrhythmia induced by orally disintegrating aripiprazole
tablets (Bosiqing(®)): a case report. Neuropsychiatr Dis Treat
2015;9::3019-21. doi: 10.2147/NDT.S91771
- [35] Alves BB, Oliveira GP, Moreira Neto MG, Fiorilli RB, Cestário
EDES. Use of atypical antipsychotics and risk of hypertension:
A case report and review literature. SAGE Open Med Case Rep
2019; 7:2050313X19841825. doi: 10.1177/2050313X19841825